SAB Biotherapeutics Management
Management criteria checks 2/4
SAB Biotherapeutics' CEO is Samuel Reich, appointed in Jan 2024, has a tenure of 2.67 years. total yearly compensation is $9.43M, comprised of 5.6% salary and 94.4% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth $76.87K. The average tenure of the management team and the board of directors is 4.3 years and 5.2 years respectively.
Key information
Samuel Reich
Chief executive officer
US$9.4m
Total compensation
| CEO salary percentage | 5.56% |
| CEO tenure | 2.7yrs |
| CEO ownership | 0.02% |
| Management average tenure | 4.3yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
Phase IIb Safeguard Trial And Autoimmune Shift Will Redefine Long Term Potential
Catalysts About SAB Biotherapeutics SAB Biotherapeutics is a clinical stage biopharmaceutical company developing fully human anti thymocyte immunoglobulin therapies for type 1 diabetes and other autoimmune diseases. What are the underlying business or industry changes driving this perspective?Is SAB Biotherapeutics (NASDAQ:SABS) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Autoimmune Disease Modifying Therapies And Regulatory Tailwinds Will Support Long Term Upside Potential
Catalysts About SAB Biotherapeutics SAB Biotherapeutics is a clinical stage biopharmaceutical company developing fully human anti thymocyte immunoglobulin, led by SAB 142 for autoimmune type 1 diabetes. What are the underlying business or industry changes driving this perspective?We Think SAB Biotherapeutics (NASDAQ:SABS) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified
SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) shareholders are no doubt pleased to see that the share price has bounced 42...Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week
SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) shareholders will have a reason to smile today, with the analysts making...Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues
Shareholders in SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) may be thrilled to learn that the analysts have just...Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) missed earnings with its latest third-quarter results, disappointing...SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial
SAB Biotherapeutics (NASDAQ:SABS) is trading 5.6% higher after the company said its fully-human polyclonal antibody platform maintains efficacy against multiple variants of several highly mutating viruses. A Phase 2a challenge trial showed SAB-176 reduced the viral load in subjects exposed to H1N1 influenza virus and improved symptoms by day four and shortened the timeframe for viral shedding. Another study showed that SAB-185 COVID-19 polyclonal antibody therapeutic candidate was effective in animal models against the majority of known SARS-CoV2 variants.What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates
The latest analyst coverage could presage a bad day for SAB Biotherapeutics, Inc. ( NASDAQ:SABS ), with the analysts...SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03
SAB Biotherapeutics press release (NASDAQ:SABS): Q2 GAAP EPS of -$0.11 beats by $0.03. Cash and cash equivalents were $16.6 million as of June 30, 2022, compared to $22.4 million on March 31, 2022, which was driven primarily by $0.7 million in further capital expansion and SAB’s second quarter cash operating loss of $5.1 million. Financial Guidance: Based on its current operating plans, SAB expects that its existing business plan, cash and cash equivalents, and anticipated cash flows as of June 30, 2022, will be sufficient to fund its operating expenses and capital expenditure requirements for the twelve months following the date our quarterly report on Form 10-Q was made available for issuance.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$22m |
| Mar 31 2026 | n/a | n/a | -US$9m |
| Dec 31 2025 | US$9m | US$525k | US$4m |
| Sep 30 2025 | n/a | n/a | -US$21m |
| Jun 30 2025 | n/a | n/a | -US$37m |
| Mar 31 2025 | n/a | n/a | -US$34m |
| Dec 31 2024 | US$3m | US$518k | -US$34m |
| Sep 30 2024 | n/a | n/a | -US$46m |
| Jun 30 2024 | n/a | n/a | -US$40m |
| Mar 31 2024 | n/a | n/a | -US$40m |
| Dec 31 2023 | US$768k | US$350k | -US$42m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$27m |
| Dec 31 2022 | US$985k | US$350k | -US$19m |
| Sep 30 2022 | n/a | n/a | -US$22m |
| Jun 30 2022 | n/a | n/a | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$18m |
| Dec 31 2021 | US$3m | US$53k | -US$17m |
Compensation vs Market: Samuel's total compensation ($USD9.43M) is above average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Samuel's compensation has increased whilst the company is unprofitable.
CEO
Samuel Reich (51 yo)
Mr. Samuel J. Reich is CEO of SAB Biotherapeutics, Inc. from January 30, 2024 and served as its Chairman and was its Executive Chairman since October 22, 2021 and serves as its Director since October 2021....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.7yrs | US$9.43m | 0.024% $ 76.9k | |
| Co-Founder | 12.7yrs | US$6.11m | 0.58% $ 1.8m | |
| Executive VP & CFO | 2.2yrs | US$2.83m | 0% $ 0 | |
| Executive VP & COO | 4.3yrs | US$1.68m | 0% $ 0 | |
| Executive VP & Chief Medical Officer | 4.3yrs | US$5.13m | 0.042% $ 134.9k | |
| Vice President of Human Resources | no data | no data | no data | |
| Senior Vice President of Product Development | no data | no data | no data | |
| Senior Vice President of Regulatory Affairs | 5.3yrs | no data | no data | |
| Senior Vice President of Clinical Operations | 1yr | no data | no data |
Experienced Management: SABS's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.8yrs | US$9.43m | 0.024% $ 76.9k | |
| Co-Founder | no data | US$6.11m | 0.58% $ 1.8m | |
| Independent Director | 7.7yrs | US$489.26k | 0% $ 0 | |
| Independent Vice Chairman | 8.7yrs | US$489.26k | 0.0063% $ 20.1k | |
| Independent Director | 3.4yrs | US$496.26k | 0% $ 0 | |
| Independent Chair of the Board | less than a year | no data | no data | |
| Independent Director | 2.8yrs | US$490.26k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of the Clinical Advisory Board & Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board & Member of Clinical Advisory Board | 6.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.5yrs | no data | no data |
Experienced Board: SABS's board of directors are considered experienced (5.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 04:35 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SAB Biotherapeutics, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eliana Merle | Barclays |
| "Eliana Merle | Barclays |
| Kumaraguru Raja | Brookline Capital Markets |